Aspire Biopharma Holdings, Inc. (ASBPW)
↓ Download CSV- Sector Manufacturing
- Incorporated E9
- Fiscal year ends Dec 31
In fiscal 2025, Aspire Biopharma Holdings, Inc. reported revenue of $6.2K. The company ran a net loss, with a net margin of -394725.1% and a gross margin of -1.9%. It held $1.31M in total assets against $7.69M in total liabilities.
Key ratios (FY2025)
-1.9%
Gross margin
-312016.9%
Operating margin
-394725.1%
Net margin
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $6.2K | — | — | — | — |
| Cost of Revenue | $6.3K | — | — | — | — |
| Gross Profit | -$116 | — | — | — | — |
| Operating Income | -$19.35M | -$1.21M | — | — | — |
| Net Income | -$24.48M | -$1.31M | $4.46M | $3.34M | — |
| EPS (Diluted) | $-16.38 | $-1.90 | — | — | — |
| Total Assets | $1.31M | $148.0K | $19.98M | $300.18M | $293.2K |
| Total Liabilities | $7.69M | $1.69M | $403.3K | $11.12M | $293.7K |
| Shareholders' Equity | -$6.38M | -$1.54M | -$487.9K | -$9.94M | -$475 |
| Operating Cash Flow | -$4.92M | -$265.2K | -$653.1K | -$1.41M | — |
| Shares Outstanding | 3.53M | 690.0K | — | — | — |